BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Gastric and GEJ cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for gastric cancer: 315 (205 sponsors; 40 newly posted in the last 180 days, 12 stopped in the last 180 days; 19 new-entrant sponsors). Momentum score 13.7, rank 49 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 5, Phase 1 105, Phase 2 123, Phase 3 46, Phase 4 3, N/A 33.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN25P2 16, NA 2, P3 5, P1 235
Astellas Pharma Global Development, Inc.10P3 4, P1 1, P2 4, P4 121
RemeGen Co., Ltd.5P3 4, P2 101
Daiichi Sankyo5NA 1, P3 2, P2 200
Akeso3NA 1, P3 210
Jiangsu HengRui Medicine Co., Ltd.3P3 2, P2 100
Ono Pharmaceutical Co., Ltd.3P2 1, P3 210
Shanghai JMT-Bio Inc.3P3 2, P2 100
Bristol-Myers Squibb BMY7NA 3, P1 1, P2 2, P3 111
Novartis Pharmaceuticals NVS4P1 2, NA 1, P3 130
Pfizer PFE4P1 2, P4 1, P3 121
Suzhou Suncadia Biopharmaceuticals Co., Ltd.4P2 3, P3 100
Jazz Pharmaceuticals JAZZ3P3 1, NA 1, P2 111
Merck Sharp & Dohme LLC MRK3P4 1, P2 1, P3 110
Advanced Accelerator Applications2P2 1, P3 100
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2P3 1, P2 101
ITM Solucin GmbH2P3 1, P1 100
RayzeBio, Inc.2P1 1, P3 102
Transcenta Therapeutics (Hangzhou) Co., Ltd.2P3 1, P2 100
Biokin (Shanghai) Biopharmaceutical Co., Ltd.1P3 100
Camurus AB1P3 100
FutureGen Biopharmaceutical (Beijing) Co., Ltd1P3 101
GE Healthcare1P3 100
LaNova Medicines Limited1P3 100
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.1P3 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Rottapharm BiotechNCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersRefractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Caactive not recruiting107
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, CoEsophageal Cancer; Gastric Cancer; Colorectal Cancerrecruiting376
2026-12 est.P2/P3RemeGen Co., Ltd.NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapGastric Cancer; Gastroesophageal Junction Adenocarcinomarecruiting90
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P2Qilu Pharmaceutical Co., Ltd.NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or GastroesophagGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinomanot yet recruiting100
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ducnot yet recruiting300
2026-12-22 est.P2Healthgen Biotechnology Corp.NCT07893600 Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.Gastric Mucosal Lesionnot yet recruiting40
2026-12-30 est.P2Teclison Ltd.NCT03259867 Combination of TATE and PD-1 Inhibitor in Liver CancerHepatocellular Carcinoma; Gastric Cancerrecruiting54
2026-12-30 est.P3AskGene Pharma, Inc.NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinomaactive not recruiting780
2026-12-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting464
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P1/P2Chimeric TherapeuticsNCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyNeuroendocrine Tumors; Colorectal Cancer; Gastric Canceractive not recruiting135
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2026-12-31 est.P2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06730581 Utidelone Capsule Monotherapy for Patients with Advanced Solid TumorsGastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancernot yet recruiting100
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-11 est.P3FutureGen Biopharmaceutical (Beijing) Co., LtdNCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable orLocally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastarecruiting486
2027-02 est.P1/P2Lumicell, Inc.NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersColorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Canceractive not recruiting66
2027-02-09 est.P2Aston Sci. Inc.NCT05771584 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerGastric Canceractive not recruiting24
2027-02-10 est.P2AstraZeneca AZNNCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)active not recruiting127

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11 est.P3AkesoNCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaGastric and Gastroesophageal Junction Adenocarcinomarecruiting506
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarHER2-positive Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting64
2026-09-30 est.P2Convalife (Shanghai) Co., Ltd.NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastanot yet recruiting28
2026-08-31 est.P3Daiichi SankyoNCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-CGastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinomaactive not recruiting490
2026-08-26 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaLocalized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma;not yet recruiting252
2026-08-14P2AstraZeneca AZNNCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.Gastric Cancer; Gastroesophageal Junction Canceractive not recruiting33
2026-08-03 est.P2Catalysis SLNCT07179237 Efficacy of Carminal in Helicobacter Pylori GastritisH Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacterrecruiting80
2026-08 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerGastric Cancer; Gastroesophageal-junction Cancerrecruiting200
2026-07-31 est.P1/P2Idience Co., Ltd.NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerGastric Canceractive not recruiting87
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06-01 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06296706 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric CancerGastric Cancerrecruiting630
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "gastric cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.